Finally, given that miR-125a and miR-223 increase in CLL patients and target both BCL-2 and STAT3, it can be concluded that miR-223 expression may be used as a suitable prognostic factor for CLL; miR125a is an appropriate marker for treatment based on the BCL2 link, too. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.